FSD Pharma’s Lucid-21-302 — an oral treatment candidate known as Lucid-MS, for all types of multiple sclerosis (MS) — was found safe and well tolerated across multiple doses in healthy volunteers, according to interim data from a Phase 1 clinical trial. The newly released data are from the…

OCS-05, a neuroprotective treatment candidate being developed by Oculis for multiple sclerosis (MS) or other causes of optic nerve inflammation, demonstrated a favorable safety and pharmacological profile in healthy volunteers, according to Phase 1 trial data. A Phase 2 trial (NCT04762017), called ACUITY, is now evaluating OCS-05’s…

New data from a Phase 2 clinical trial testing vidofludimus calcium, Immunic Therapeutics’ novel oral treatment candidate for relapsing-remitting multiple sclerosis (RRMS), show promising safety and efficacy, according to the company’s chief medical officer. The therapy was found to safely reduce brain lesions and prevent disability progression in…

Ocrevus (ocrelizumab) is a safe and effective treatment for patients under 18 with highly active relapsing-remitting multiple sclerosis (RRMS), a small study from Turkey suggests. Over about 2.5 years of the treatment, these pediatric patients experienced no relapses or MRI activity, and their disability level also improved, indicating…

PB006, a biosimilar to Biogen’s approved treatment Tysabri (natalizumab), showed similar safety and efficacy as the original medication in people with relapsing-remitting MS (RRMS), according to data from a Phase 3 clinical trial. “The Antelope trial reported equivalence between [PB006 and Tysabri] treatment across efficacy, safety, and secondary…

Autologous hematopoietic stem cell transplant (aHSCT) has shown some promise as a treatment option for highly active relapsing-remitting multiple sclerosis (RRMS), but more clinical evidence is needed to support its use, a team of researchers in the U.K. suggest. “Uncertainty remains as to how aHSCT compares with current…

Temelimab, GeNeuro’s investigative treatment for multiple sclerosis (MS), showed a favorable safety profile when given alongside rituximab, according to preclinical safety experiments performed in preparation for the company’s new Phase 2 trial involving patients with relapsing MS. Data from the preclinical experiments, along with details of…